Of note, tumours expressing high levels of the cystine-glutamate antiporter xCT (SLC7A11) are heavily dependent on the PPP to supply reducing power in the form of NADPH [176], and GLUT inhibition selectively kills SLC7A11 high cancer cells in-vitro and in-vivo [177], presenting a metabolic vulnerability that can be targeted. This evidence concerns the gene SLC7A11 and cancer.